Key result
The median total hK2 concentration was 0.079 microg/L in patients with prostate cancer compared to 0.022 microg/L in controls, with a wide variation in the free-to-total hK2 ratio.
Population
426 noncharacterized serum samples from males and plasma from 103 patients with confirmed prostate cancer
Authors
Loading...
Does not yet support routine hK2 use in prostate cancer diagnosis; leaves open its value pending diagnostic accuracy studies.
Cross-Sectional (n=529)
A newly developed sensitive immunoassay for free and total hK2 demonstrates wide variation in the free-to-total hK2 ratio in prostate cancer patients, indicating its potential utility for diagnostic accuracy studies.
Väisänen et al. (2004) conducted a cross-sectional in Prostate cancer (n=529). Free and total human glandular kallikrein 2 (hK2) measurement vs. Noncharacterized male serum samples was evaluated on Free and total hK2 concentrations. The median total hK2 concentration was 0.079 microg/L in patients with prostate cancer compared to 0.022 microg/L in controls, with a wide variation in the free-to-total hK2 ratio.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: